Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte boss Doerfler excited by gene-editing licence deal

Doug Doerfler, chief executive of MaxCyte, runs through the firm's first commercial licence deal in the gene-editing space.
Under the deal, CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.
CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.
"It's a very exciting time for the company and it's really a pleasure to be working with this advanced group that’s working in the area of inherited blood disorders," said Doerfler.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Article
October 10 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use